Amyloidosis: Diagnosis and management

Research output: Contribution to journalArticle

59 Citations (Scopus)

Abstract

Amyloidosis is a rare plasma cell proliferative disorder. The annual incidence in Olmsted County, Minnesota, is 8 in 1,000,000 patients. This is a difficult disorder to diagnose, because the symptoms at presentation are vague and include dyspnea, paresthesias, edema, weight loss, and fatigue. The clinical syndromes at the time of presentation include nephrotic-range proteinuria with or without renal failure, cardiomyopathy, "atypical multiple myeloma," hepatomegaly, and autonomic or peripheral neuropathy. The serum immunoglobulin free light chain assay has been an important step forward in classifying systemic amyloidosis as an immunoglobulin light chain form and in monitoring therapy. Recently, the importance of serum cardiac biomarkers in assessing outcome has been recognized. New therapies developed over the past 5 years include high-dose chemotherapy with stem cell reconstitution, combinations of alkylating agents with dexamethasone, and, most recently, thalidomide.

Original languageEnglish (US)
Pages (from-to)208-219
Number of pages12
JournalClinical Lymphoma and Myeloma
Volume6
Issue number3
DOIs
StatePublished - Nov 2005

Fingerprint

Immunoglobulin Light Chains
Amyloidosis
Thalidomide
Hepatomegaly
Paresthesia
Alkylating Agents
Peripheral Nervous System Diseases
Plasma Cells
Serum
Multiple Myeloma
Cardiomyopathies
Proteinuria
Dyspnea
Dexamethasone
Renal Insufficiency
Fatigue
Weight Loss
Edema
Stem Cells
Biomarkers

Keywords

  • Amyloid
  • Monoclonal gammopathy
  • Multiple myeloma
  • Stem cell transplantaion

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

Amyloidosis : Diagnosis and management. / Gertz, Morie; Lacy, Martha; Dispenzieri, Angela; Hayman, Suzanne R.

In: Clinical Lymphoma and Myeloma, Vol. 6, No. 3, 11.2005, p. 208-219.

Research output: Contribution to journalArticle

@article{8e0e467528234c77a57135838704d0da,
title = "Amyloidosis: Diagnosis and management",
abstract = "Amyloidosis is a rare plasma cell proliferative disorder. The annual incidence in Olmsted County, Minnesota, is 8 in 1,000,000 patients. This is a difficult disorder to diagnose, because the symptoms at presentation are vague and include dyspnea, paresthesias, edema, weight loss, and fatigue. The clinical syndromes at the time of presentation include nephrotic-range proteinuria with or without renal failure, cardiomyopathy, {"}atypical multiple myeloma,{"} hepatomegaly, and autonomic or peripheral neuropathy. The serum immunoglobulin free light chain assay has been an important step forward in classifying systemic amyloidosis as an immunoglobulin light chain form and in monitoring therapy. Recently, the importance of serum cardiac biomarkers in assessing outcome has been recognized. New therapies developed over the past 5 years include high-dose chemotherapy with stem cell reconstitution, combinations of alkylating agents with dexamethasone, and, most recently, thalidomide.",
keywords = "Amyloid, Monoclonal gammopathy, Multiple myeloma, Stem cell transplantaion",
author = "Morie Gertz and Martha Lacy and Angela Dispenzieri and Hayman, {Suzanne R.}",
year = "2005",
month = "11",
doi = "10.3816/CLM.2005.n.048",
language = "English (US)",
volume = "6",
pages = "208--219",
journal = "Clinical Lymphoma, Myeloma and Leukemia",
issn = "2152-2669",
publisher = "Cancer Media Group",
number = "3",

}

TY - JOUR

T1 - Amyloidosis

T2 - Diagnosis and management

AU - Gertz, Morie

AU - Lacy, Martha

AU - Dispenzieri, Angela

AU - Hayman, Suzanne R.

PY - 2005/11

Y1 - 2005/11

N2 - Amyloidosis is a rare plasma cell proliferative disorder. The annual incidence in Olmsted County, Minnesota, is 8 in 1,000,000 patients. This is a difficult disorder to diagnose, because the symptoms at presentation are vague and include dyspnea, paresthesias, edema, weight loss, and fatigue. The clinical syndromes at the time of presentation include nephrotic-range proteinuria with or without renal failure, cardiomyopathy, "atypical multiple myeloma," hepatomegaly, and autonomic or peripheral neuropathy. The serum immunoglobulin free light chain assay has been an important step forward in classifying systemic amyloidosis as an immunoglobulin light chain form and in monitoring therapy. Recently, the importance of serum cardiac biomarkers in assessing outcome has been recognized. New therapies developed over the past 5 years include high-dose chemotherapy with stem cell reconstitution, combinations of alkylating agents with dexamethasone, and, most recently, thalidomide.

AB - Amyloidosis is a rare plasma cell proliferative disorder. The annual incidence in Olmsted County, Minnesota, is 8 in 1,000,000 patients. This is a difficult disorder to diagnose, because the symptoms at presentation are vague and include dyspnea, paresthesias, edema, weight loss, and fatigue. The clinical syndromes at the time of presentation include nephrotic-range proteinuria with or without renal failure, cardiomyopathy, "atypical multiple myeloma," hepatomegaly, and autonomic or peripheral neuropathy. The serum immunoglobulin free light chain assay has been an important step forward in classifying systemic amyloidosis as an immunoglobulin light chain form and in monitoring therapy. Recently, the importance of serum cardiac biomarkers in assessing outcome has been recognized. New therapies developed over the past 5 years include high-dose chemotherapy with stem cell reconstitution, combinations of alkylating agents with dexamethasone, and, most recently, thalidomide.

KW - Amyloid

KW - Monoclonal gammopathy

KW - Multiple myeloma

KW - Stem cell transplantaion

UR - http://www.scopus.com/inward/record.url?scp=33644877690&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33644877690&partnerID=8YFLogxK

U2 - 10.3816/CLM.2005.n.048

DO - 10.3816/CLM.2005.n.048

M3 - Article

C2 - 16354326

AN - SCOPUS:33644877690

VL - 6

SP - 208

EP - 219

JO - Clinical Lymphoma, Myeloma and Leukemia

JF - Clinical Lymphoma, Myeloma and Leukemia

SN - 2152-2669

IS - 3

ER -